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Abstract 
Introduction Several antihypertensive drugs are photosensitizing and may promote the 
development of malignant melanoma (MM), but evidence remains inconsistent. We 
sought to quantify the association between use of antihypertensive drugs and MM risk.  
Methods We systematically searched Pubmed, Embase, and CENTRAL from inception 
to August 17, 2017 to identify observational studies that reported the MM risk 
associated with the use of antihypertensive drugs. A random-effects meta-analysis was 
used to estimate the odds ratio (OR) with 95% confidence interval (CI).  
Results Overall, we included eight observational studies (two cohort studies and six 
case-controlled studies). Compared with non-use, use of diuretics (OR, 1.10; 95% CI, 
1.03 to 1.17) or beta-adrenergic blocking agents (OR, 1.19; 95% CI, 1.04 to 1.37) was 
significantly associated with increased risk of MM. The use of angiotensin converting 
enzyme inhibitors (OR, 1.08; 95% CI, 0.95 to 1.23), angiotensin II receptor blockers 
(OR, 1.12; 95% CI, 0.95 to 1.31), and calcium channel blockers (OR, 1.12; 95% CI, 0.72 
to 1.74) was not significantly associated with increased risk of MM. 
Conclusions Current evidence from observational studies suggests that use of 
diuretics or beta-adrenergic blocking agents may be associated with increased risk of 
MM. Further large well-conducted prospective studies are required to confirm our 
findings.  
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Key points 
• Epidemiologic studies reported conflicting results on possible associations between 
use of antihypertensive drugs and risk of malignant melanoma (MM).  
• Current evidence from observational studies indicates that use of diuretics or β-
blockers may be positively associated with MM.  
• Further large prospective studies with dose- or time-response analysis and clear 
adjustment for confounders are warranted.  
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1 Introduction 
Skin cancers are the most common human cancers, mainly caused by exposure to 
ultraviolet radiation (UVR) [1, 2]. However, their incidence is still increasing worldwide 
[3], despite growing awareness of the harmful effects of sun exposure [4]. It is estimated 
that more than 8,500 people in the United States are diagnosed with skin cancer every 
day [5]. Malignant melanoma (MM), the most serious skin cancer, accounts for less than 
1% of skin cancer cases, but is responsible for most skin cancer deaths [6]. Several risk 
factors, such as UVR exposure, number of melanocytic nevi, familiar history, and 
genetic susceptibility, have been proposed to explain the incidence of MM [7]. Recently, 
some evidence indicated that drug use might be associated with increased risk of MM 
[8, 9].  
Antihypertensive drugs have been widely used to treat hypertension as well as other 
conditions including heart failure and arrhythmias [10]. It is estimated that about one-
third of U.S. adults suffer from hypertension [11] and are likely to take antihypertensive 
drugs. However, several antihypertensive drugs are described as photosensitizing and 
may act as co-carcinogens with UVR to promote MM development [12]. Among the five 
major classes of antihypertensive drugs – angiotensin-converting enzyme inhibitors 
(ACE inhibitors), angiotensin receptor blockers (ARBs), beta-adrenergic blocking agents 
(β-blockers), calcium channel blockers (CCBs), and diuretics, use of diuretics was found 
to be associated with an increased risk of MM in some studies [12, 13]. Similarly, a 
positive association was also detected between use of β-blockers and risk of MM [9, 
14]. On the other hand, some studies did not find a positive association between either 
diuretics [9, 14] or β-blockers [15] and risk of MM. These inconsistent findings might 
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result from the small sample size and varieties in study durations and study populations 
in individual reports. Little is known about the risk of MM among individuals taking ACE 
inhibitors, ARBs, or CCBs. Moreover, there has been no previous systematic review 
and meta-analysis of the association between use of antihypertensive drugs and risk of 
MM. We therefore sought to conduct this meta-analysis to determine whether any of the 
above five major classes of antihypertensive drugs was associated with MM risk. 
2 Methods 
2.1 Search strategy and study selection  
The electronic databases including PubMed, Embase, and Cochrane Central Register 
of Controlled Trials (CENTRAL) were systematically searched to identify observational 
studies (cohort and case-control studies) that evaluated the association between 
exposure to antihypertensive drugs and risk of MM. All of the databases were searched 
from inception to August 17, 2017 using combined terms (Supplementary file 1) 
without any restriction. In addition, the reference lists of relevant reviews and meta-
analyses were also checked to identify additional studies.  
After excluding duplicate citations, two reviewers (HT and SF) independently reviewed 
titles and abstracts of remaining studies to identify potential studies, which were further 
evaluated by retrieving their full texts. We included the studies that fulfilled the following 
inclusion criteria: 1) use of any antihypertensive drug as the exposure and no use of 
particular antihypertensive drug as the reference; 2) reported the outcome of MM; 3) 
reported the odds ratio (OR), relative risk (RR), hazard ratio (HR), or relevant estimates 
with 95% confidence intervals (CIs) or sufficient data to determine 95% CIs; and 4) 
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observational studies including cohort studies or case-control studies. We searched 
above databases without any language restriction and included papers published in 
other languages. Of the potential studies, none was published in a language other than 
English. For multiple studies using the same populations, only the study with latest or 
longest follow-up was included. If the article included multiple sample from different 
database and reported their outcomes separately, we considered it as multiple studies. 
We excluded abstracts and unpublished studies due to limited information to assess 
quality. Furthermore, to prevent double-counting from duplications, two reviewers (HT 
and SF) double checked the data source and populations of the included studies.  
2.2 Data extraction and quality assessment  
Two reviewers (HT and SF) independently extracted data and assessed the quality of 
each study. We collected the following information: study design, data source, number 
of participants, age (years), gender (%), selection criteria, exposure definition, reference 
definition, adjusted covariates, and the adjusted estimates. We also extracted data for 
further dose/time response analyses. In addition, we assessed the quality of studies 
according to Newcastle-Ottawa quality-assessment scale (NOS) [16], which ranges 
from 0 to 9, with a higher score indicating better quality. In case of any missing 
information, we contacted the original author for clarification. Any disagreements were 
resolved by consensus or referral to a third reviewer (JH). 
2.3 Statistical analysis  
Due to similarities among these effect measures (HR, RR, and OR) when the number of 
events is low (< 5%) [17], ORs with 95% CIs were used to pool the outcome data in 
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random-effects models. P values < 0.05 were considered statistically significant. 
Heterogeneity was quantified using the I² statistic, with I2 of < 25%, ≥ 25% and < 75%, 
and ≥ 75% indicating low, medium, and high heterogeneity, respectively [18]. Separate 
analyses were carried out for each class of antihypertensive drug. Furthermore, 
additional analyses were performed if there were sufficient data (at least six studies 
included [19]). A subgroup analysis was performed by type of design, region of study, 
effect measure, and study quality to examine the source of heterogeneity. To present 
the development of evidence, we performed a cumulative meta-analysis based on data 
of publication to determine the year in which the association became significant. A 
sensitivity analysis was carried out to evaluate the effect of each study on the overall 
estimate by removing one study at a time. In addition, publication bias for risk of MM 
was assessed using Begg’s and Egger’s tests. All statistical analyses were performed 
with STATA (Version 14; Stata Corp., College Station, TX).  
3 Results 
Of 3360 citations retrieved from electronic databases, eight observational studies, i.e., 
two cohort studies [13, 20] and six case-control studies [9, 12, 14, 15, 21-23],met the 
eligibility criteria and were included in our meta-analysis (Fig. 1). The main 
characteristics of the included studies are presented in Table 1. Studies were published 
between 1996 and 2017. Six studies were carried out in Europe and two in the United 
States. Diuretics were used in six studies, ACE inhibitors in four studies, ARBs in three 
studies, β-blockers in three studies, and CCBs in two studies. OR was reported in five 
studies as an effect measure, incidence rate ratio (IRR) was reported in two studies, 
and RR was reported in one study. The included studies were of moderate or high 
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quality: Four were assessed as high quality with a NOS score 8 out of 9, and the 
remaining studies were assessed as medium quality, with scores from 5 to 7 
(Supplementary Table 2). 
3.1 Diuretics and risk of MM  
The pooled estimates of six studies showed that use of diuretics was associated with 
significantly increased risk of MM compared with non-use (OR, 1.10, 95% CI, 1.03 to 
1.17), with no evidence of heterogeneity (I2 = 0%) (Fig. 2). Subgroup analyses by study 
design, region of study, quality of study, and effect measure were performed and the 
results presented in Supplementary Table 3. A significantly increased risk of MM was 
identified in studies performed in European populations (OR, 1.10; 95% CI, 1.03 to 
1.17), studies with high quality (OR, 1.09; 95% CI, 1.02 to 1.17), and studies reporting 
IRR as an effect measure (OR, 1.12; 95% CI, 1.03 – 1.21). Our cumulative meta-
analysis indicated that an increased risk of MM had been evident since 2008 (OR, 1.18; 
95% CI, 1.01 to 1.39) (Fig. 3). Sensitivity analyses excluding one study at a time 
showed that no study significantly affected the overall estimates (Supplementary Fig. 
1). There was no evidence of publication bias based on Egger’s test (P = 0.18) and 
Begg’s test (P = 0.26).  
3.2 β-blockers and risk of MM 
Three studies reported data on the association between β-blockers and risk of MM. 
When we pooled analysis of these studies, we found a significantly increased risk of 
MM (OR, 1.19; 95% CI, 1.04 to 1.37), with low evidence of heterogeneity (I2 = 11.0%) 
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(Fig. 2). However, further analysis (e.g., subgroup analysis) was hampered due to the 
limited number of studies included. 
3.3 Other classes of antihypertensive drugs and risk of MM 
We identified positive associations between other classes of antihypertensive drugs and 
risk of MM, but they did not reach statistical significance (Fig. 2). For ACE inhibitors, the 
OR for risk of MM was 1.08 (95% CI, 0.95 to 1.23) in a pooled analysis of the data from 
four studies. There was low evidence of heterogeneity (I2 = 3.4%). Three studies 
reported the risk of MM associated with ARBs, and their pooled analysis showed that 
OR for the risk of MM was 1.12 (95% CI, 0.95 to 1.31), with no evidence of 
heterogeneity (I2 = 0%). The OR between CCBs and risk of MM was 1.12 (95% CI, 0.72 
to 1.74), based on data from two studies, but significant heterogeneity was found (I2 = 
52.6%).  
3.4 Dose/time-response analyses 
One study identified a trend of an increase in risk of MM among the users of 
indapamide (one type of diuretic) only, with an increase in IRR from 3.85 (95% CI, 1.47 
to 10.1) in a ≥ 1 year latency to 6.06 (95% CI, 1.78 to 20.7) in a ≥ 5 year latency [12]. 
One study found that the long-term use of ARBs, ACE inhibitors, β-blockers, and CCBs 
was associated with increased risk of MM, but not short term use [14]. However, the 
study by Koomen et al. did not detect either a dose or time-response for ACE inhibitors 
or ARBs [21]. 
4 Discussion 
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Our meta-analysis of eight observational studies involving a large overall number of 
participants and incident cases of MM provides evidence that use of diuretics or β-
blockers is associated with a slight increase in the risk of MM. No significantly increased 
risk of MM was observed among patients using other classes of antihypertensive drugs 
(including ACE inhibitors, ARBs, and CCBs). For diuretics, our cumulative meta-
analysis indicated that use was significantly associated with an increased risk of MM 
start in 2008. In addition, a significantly increased risk of MM was identified in studies 
performed in Europe, high quality studies, and studies reporting IRR as an effect 
measure. There was no evidence of publication bias. However, our results should be 
interpreted with caution due to the limited number of studies included.  
The first-line treatment for hypertension usually involves diuretics [24]. It is estimated 
that in 2004, about one-third of patients in the United States visiting a physician to 
address hypertension were prescribed diuretics [25]. Among antihypertensive drugs, 
diuretics carry the highest risk of photosensitivity reactions [26]. However, despite the 
wide use of diuretics, little attention has been paid to the possible associated risk of 
MM. There is some evidence that a photosensitizing reaction followed by sun exposure 
may increase the likelihood of sunburn and photo-damage, which increases risk of MM 
[27]. It is well known that drug-induced photosensitivity may act as a co-carcinogen with 
UVR to promote MM development [12]. Some epidemiologic studies have found 
increased risk of MM associated with diuretics [12, 13, 20]. Consistent with those 
findings, our results from this meta-analysis showed that use of diuretics was 
significantly associated with increased risk of MM. Furthermore, our stratified analysis 
indicated a significantly increased risk of MM in European populations, but not in US 
11  
populations, though this might be caused by the limited number of patients included in 
our meta-analysis. However, our meta-analysis did not differentiate further among 
diuretics, and not all diuretics had the same propensity to induce photosensitivity [28]. 
Jensen et al. observed a trend of an increase in risk of MM among the users of 
indapamide, but not other diuretics [12].   
It was interesting to find some evidence indicating a slightly increased risk of MM 
among patients taking β-blockers. Some β-blockers (e.g., sotalol) were considered 
photosensitizing [29], and therefore might increase MM development by acting as co-
carcinogens with UVR. In a population based, matched case-control study from 
southern Sweden, Westerdahl et al. found a 70% increased risk in patients who used β-
blockers as compared with non-users [9]. Recently, one population-based case-control 
study performed in northern Denmark found a weak association between use of β-
blockers and risk of MM [14]. However, due to the limited number of studies we 
included, whether the weak association may be caused by chance influenced by 
confounders or represents a true association needs to be further investigated. 
We found some evidence suggestion of increased risk of MM associated with other 
classes of antihypertensive drugs (ACE inhibitors, ARBs, and CCBs), but the 
associations were not statistically significant, which might be caused by our limited 
sample. Additionally, one study found that long-term use of ACE inhibitors, ARBs, β-
blockers, or CCBs was associated with increased risk of MM [14]. However, little is 
known about the possible mechanisms underlying any carcinogenic risk associated with 
other classes of antihypertensive drugs. An explanation might be that some 
antihypertensive drugs have been reported to elicit photosensitivity and phototoxicity, 
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which might mediate an increased risk of MM associated with UVR [14]. However, we 
did not find a consistently increased risk of MM across these classes of antihypertensive 
drugs, which might be related to the fact that photosensitizing effects differed based on 
drug classes or pathways involved. In contrast, some evidence from both experimental 
and epidemiologic studies indicated some chemopreventive effects of ACE inhibitors 
and ARBs against cancer, with possible mechanisms of action including inhibition of 
matrix metalloprotease activity, reduced expression of vascular endothelial growth 
factor, and interference with the renin-angiotensin system [30]. In our meta-analysis, the 
use of ACE inhibitors or ARBs did not seem to protect against the development of MM, 
which was consistent with published observational studies [13-15, 21]. Therefore, 
further large well-conducted studies involving dose-response analyses are required to 
clarify the MM risk among these classes of antihypertensive drugs. 
Our study has two strengths. First, we systematically searched electronic databases to 
include all relevant studies. It is important to note that this is the first meta-analysis to 
address the association between antihypertensive drugs and risk of MM. Second, to 
confirm the robustness of our findings, pre-specified subgroup analysis and sensitivity 
analysis were performed. We also acknowledge that our meta-analysis has several 
limitations. First, common risk factors for MM, such as sun exposure, ethnicity, and 
smoking status could not be adjusted for in the subgroup analysis, due to inconsistent 
control for potential confounders from included studies. Second, one potential 
confounder, health seeking behavior, may lead to detection bias. Individuals under 
hypertension management may be more likely to seek medical advice and be subject to 
increased surveillance, which may increase probability of disease diagnosis. However, 
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we did not detect an increased risk of MM across all classes of antihypertensive drugs, 
which suggested that the increased risk might not be entirely due to increased scrutiny. 
Third, of the studies we analyzed, only one (Koomen et al 2009) provided the 
information on cumulative doses or cumulative durations [21], which prevented us from 
performing a further dose-response analysis or time dependency analysis. Finally, due 
to the limited number of studies included, our results for ACE inhibitors, ARBs, β-
blockers, and CCBs were inconsistent and therefore hinder any firm conclusions. 
5 Conclusions 
Our meta-analysis indicates that use of diuretics or β-blockers may be associated with 
increased risk of MM. There was little evidence supporting increased risk of MM with 
other classes of antihypertensive drugs (ACE inhibitors, ARBs, and CCBs). Further 
large well-conducted prospective studies with dose- or time-response analyses and 
clear adjustment for confounders are required to confirm our findings. 
  
14  
Compliance with Ethical Standards  
Ethical approval and patient consent were not required for this study. 
Funding No sources of funding were used to assist in the preparation of this study  
Conflict of interest Huilin Tang, Shuangshuang Fu, Suodi Zhai, Yiqing Song, and Jiali 
Han have no conflicts of interest that are directly relevant to the content of this study.  
15  
References 
1. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J 
Dermatol. 1997;38 (Suppl 1):S1-6. 
2. Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk 
factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev. 
2014;23(6):1080-9. 
3. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et 
al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch 
Dermatol. 2010;146(3):283-7. 
4. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 
2010;375(9715):673-85. 
5. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of 
nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. 
JAMA Dermatol. 2015;151(10):1081-6. 
6. American Cancer Society. Cancer facts and figures 2016. 2016.  
http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-
047079.pdf. Accessed Decmenber 27,2016. 
7. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, 
pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005-11. 
8. Tang H, Wu W, Fu S, Zhai S, Song Y, Han J. Phosphodiesterase type 5 inhibitors 
and risk of melanoma: A meta-analysis. J Am Acad Dermatol. 2017;77(3):480-8 e9. 
9. Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N. Risk of malignant 
melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J 
16  
Cancer. 1996;73(9):1126-31. 
10. Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116-25. 
11. Merai R, Siegel C, Rakotz M, Basch P, Wright J, Wong B, et al. CDC Grand 
Rounds: A Public Health Approach to Detect and Control Hypertension. MMWR Morb 
Mortal Wkly Rep. 2016;65(45):1261-4. 
12. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. 
Use of photosensitising diuretics and risk of skin cancer: a population-based case-
control study. Br J Cancer. 2008;99(9):1522-8. 
13. Nardone B, Majewski S, Kim AS, Kiguradze T, Martinez-Escala EM, Friedland R, et 
al. Melanoma and non-Melanoma skin cancer associated with angiotensin-converting-
enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. 
Drug Saf. 2017;40(3):249-55. 
14. Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sorensen HT. Use of 
antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 
2015;29(8):1545-54. 
15. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, et al. Calcium 
channel blockers and the risk of cancer. JAMA. 1998;279(13):1000-4. 
16. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in 
meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.  
Accessed Decmenber 27,2016. 
17. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J 
Clin Epidemiol. 2002;55(9):893-9. 
17  
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 
2002;21(11):1539-58. 
19. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of 
the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat 
Med. 1998;17(17):1923-42. 
20. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing 
medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev. 
2010;19(11):2942-9. 
21. Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Melanoma incidence and 
exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers. Cancer Epidemiol. 2009;33:391-5. 
22. de Vries E, Trakatelli M, Kalabalikis D, Ferrandiz L, Ruiz-de-Casas A, Moreno-
Ramirez D, et al. Known and potential new risk factors for skin cancer in European 
populations: a multicentre case-control study. Br J Dermatol. 2012;167 Suppl 2(Suppl 
2):1-13. 
23. Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. 
Photosensitizing agents and the risk of non-melanoma skin cancer: A population-based 
case-control study. J Invest Dermatol. 2013;133(8):1950-5. 
24. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, 
et al. 2014 evidence-based guideline for the management of high blood pressure in 
adults: report from the panel members appointed to the Eighth Joint National Committee 
(JNC 8). JAMA. 2014;311(5):507-20. 
25. Stafford RS, Monti V, Furberg CD, Ma J. Long-term and short-term changes in 
18  
antihypertensive prescribing by office-based physicians in the United States. 
Hypertension. 2006;48(2):213-8. 
26. Selvaag E, Thune P. Phototoxicity to sulphonamide-derived oral antidiabetics and 
diuretics: investigations in hairless mice. Photodermatology Photoimmunology & 
Photomedicine. 1997;13(1-2):4-8. 
27. Stern RS. Photocarcinogenicity of drugs. Toxicol Lett. 1998;102-103:389-92. 
28. Diffey BL, Langtry J. Phototoxic potential of thiazide diuretics in normal subjects. 
Arch Dermatol. 1989;125(10):1355-8. 
29. Zammit ML. Photosensitivity : light, sun and pharmacy. Journal of the Malta College 
of Pharmacy 2010(16):12-7. 
30. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting 
enzyme inhibitors for cancer treatment? Acta Oncol. 2004;43(2):142-52. 
19  
Table 1 Characteristics of included studies 
Study Study 
design  
Data source Durati
on 
(years) 
No. of 
participa
nts  
Age 
(years
) 
Men 
(%) 
Selection 
criteria 
Exposur
e 
definitio
n 
Reference 
definition 
 
Meas
ure 
Covariate 
adjustment 
Westerdahl 
et al. 1996 
[9] 
Case-
control 
study 
Regional 
Tumor 
Registry in 
Southern 
Sweden; 1988 
to 1990; 
Sweden 
NR MM: 
348; 
Control: 
560 
15-
75 
46.6 Participants 
aged 15-75 
years and 
diagnosed 
with MM, two 
healthy 
controls 
matched by 
sex, age 
Diuretics;
β-
blockers 
Never use of 
the particular 
drug class 
OR History of sunburns 
and host factors 
Rosenberg 
et al. 1998 
[15] 
Case-
control 
study 
Hospitals in 
Baltimore; 
1983 to 1996; 
US 
3.8  MM: 
597; 
Controls
: 6492 
54 NR Patients with 
MM and 
selected 
controls aged 
40-69 years  
CCBs; β-
blockers; 
ACEi 
Never use of 
the particular 
drug class 
RR Age, interview year, 
body mass index, 
race, and years of 
education, etc. 
Jensen et 
al. 2008 [12] 
Case-
control 
study 
Danish 
Cancer 
Registry; 
North Jutland 
County; 1989 
to 2003; 
Denmark 
NR MM: 
1010; 
BCC: 
594; 
SCC: 
1129;  
Controls
: 32,412 
NR NR Patients 
registered with 
a first primary 
diagnosis of 
BCC, SCC, or 
MM, and four 
population 
controls 
selected for 
each case 
Diuretics Never use of 
diuretics 
IRR Prior hospitalization 
for selected chronic 
diseases and use 
of glucocorticoids. 
Koomen et 
al, 2009 [21] 
Case-
control 
study 
PHARMO 
linkage 
network and 
the PALGA 
database; 
1991 to 2004; 
Netherlands 
≥ 3  MM: 
1272; 
Controls
: 6520 
55 40 Patients with 
primary MM 
between 1991 
and 2004, 
aged ≥18 
years and 
having 3 years 
of follow-up 
prior to 
diagnosis, and 
ACEi or 
ARB for 
at least 
six 
months 
Non exposed 
to particular 
drug class 
OR Total number of 
unique medical 
diagnoses and the 
use of statins 
20  
matched 
controls 
De Vries et 
al. 2012 [22] 
Case-
control 
study 
Multicenter, 
hospital-
based, case–
control study 
was carried 
out in Finland, 
Germany, 
Greece, Italy, 
Malta, Poland, 
Scotland and 
Spain; NR; 
Europe 
NR MM:360
; 
SCC:40
9; 
BCC:60
2; 
Controls
:1550 
67 56 Patients 
recently 
diagnosed 
with SCC, 
BCC, or MM 
(≥18 years) 
and matched 
controls 
Thiazide 
diuretics 
at least 
for 3 
months 
 
No use for 
more than 3 
months 
 
 
 
OR 
Age, sex, 
phototype, and 
country 
Schmidt et 
al. 2015 [14] 
Case-
control 
study  
Northern 
Denmark 
using various 
registries 
linked by the 
CPR numbers; 
1991 to 2010; 
Denmark 
Maximize: 
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SCC: 
2,282; 
BCC:17, 
242, 
MM:3,6
60; 
controls:
231,743 
67 46 Aged ≥20 
years with a 
first-time 
diagnosis of 
SCC, BCC, or 
MM and 10 
matched 
controls 
Β-
blockers, 
ACEi, 
ARBs, 
CCBs, or 
diuretics 
for > 2 
prescripti
ons 
before 
the index 
date 
Non-users 
with ≤ 2 
prescriptions 
of any 
antihypertens
ive drug 
OR CCI score, hospital-
diagnosed obesity, 
and use of 
systemic 
glucocorticoids, 
aspirin, non-aspirin 
NSAIDs, and 
statins 
Kaae et al. 
2010 [20] 
Cohort 
study 
Danish 
national 
registers;1995 
to 2006; 
Denmark 
NR 4,761,7
49 
participa
nts 
NR NR Patients 
identified from 
Danish 
Cancer 
Registers filled 
at least one 
prescription 
for 
photosensitizi
ng medication 
Diuretics Never users 
of diuretics 
IRR Age, period, sex, 
and education 
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Nardone et 
al. 2017 [13] 
Cohort 
study 
Northwestern 
Medicine 
Enterprise 
Data 
Warehouse; 
2004 to 2015; 
US 
4  ACEi: 
27,134, 
Control:
81,399; 
ARBs:1
3,818, 
Control:
41,454;
Thiazide
s: 
15,166, 
Control: 
45,498  
NR 43.4 Patient age 
range 18-89 
years, one or 
more written 
orders for an 
ACEi, ARB, or 
thiazides; 3 
matched 
individuals 
with no 
documented 
order for any 
antihypertensi
ve drug 
ACEi, 
ARB, or 
thiazides 
Non exposed 
to particular 
drug class 
OR Age, gender, race, 
and CCI 
ACEi angiotensin converting enzyme inhibitors, ARBs angiotensin II receptor blockers, BCC basal cell carcinoma, β-
blockers beta-adrenergic blocking agents, CCBs calcium channel blockers, CCI charlson comorbidity index, IRR 
incidence rate ratio, MM malignant melanoma, NR not reported, NSAID non-steroidal anti-inflammatory drug, OR odds 
ratio, RR relative risk, SCC squamous cell carcinoma
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Figure legends:   
Fig. 1 Flow chart of the identification of eligible studies  
Fig. 2 Meta-analysis of the association between use of antihypertensive drugs and risk 
of malignant melanoma. Definitions of exposure and reference are presented in Table 
1ACE inhibitors angiotensin converting enzyme inhibitors, ARBs angiotensin II receptor 
blockers, β-blockers beta-adrenergic blocking agents, CCBs calcium channel blockers, 
CI confidence interval, MM malignant melanoma 
Fig. 3 Cumulative meta-analysis of studies ordered by year of publication for the 
association between use of diuretics and risk of malignant melanoma. The studies are 
added at one time according to year of publication and the results are summarized as 
each new study is added. Definitions of exposure and reference are presented in Table 1. 
CI confidence interval, MM malignant melanoma  
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Figure 3 
 
 
 
 
 
 
 
 
 
